195 related articles for article (PubMed ID: 24067434)
21. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.
Levine AP; Chan MMY; Sadeghi-Alavijeh O; Wong EKS; Cook HT; Ashford S; Carss K; Christian MT; Hall M; Harris CL; McAlinden P; Marchbank KJ; Marks SD; Maxwell H; Megy K; Penkett CJ; Mozere M; Stirrups KE; Tuna S; Wessels J; Whitehorn D; ; ; Johnson SA; Gale DP
J Am Soc Nephrol; 2020 Feb; 31(2):365-373. PubMed ID: 31919107
[TBL] [Abstract][Full Text] [Related]
22. The clinical significance of plasma CFHR 1-5 in lupus nephropathy.
Hu X; Liu H; Du J; Chen Y; Yang M; Xie Y; Chen J; Yan S; Ouyang S; Gong Z
Immunobiology; 2019 May; 224(3):339-346. PubMed ID: 30975435
[TBL] [Abstract][Full Text] [Related]
23. Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces.
Chen Q; Manzke M; Hartmann A; Büttner M; Amann K; Pauly D; Wiesener M; Skerka C; Zipfel PF
J Am Soc Nephrol; 2016 May; 27(5):1413-25. PubMed ID: 26432903
[TBL] [Abstract][Full Text] [Related]
24. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
25. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far.
Larsen CP; Walker PD
Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589
[No Abstract] [Full Text] [Related]
26. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
27. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
28. Regulating complement in the kidney: insights from CFHR5 nephropathy.
Gale DP; Pickering MC
Dis Model Mech; 2011 Nov; 4(6):721-6. PubMed ID: 22065842
[TBL] [Abstract][Full Text] [Related]
29. C3 glomerulonephritis and CFHR5 nephropathy.
Gale DP; Maxwell PH
Nephrol Dial Transplant; 2013 Feb; 28(2):282-8. PubMed ID: 23125424
[TBL] [Abstract][Full Text] [Related]
30. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
31. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.
Chauvet S; Roumenina LT; Bruneau S; Marinozzi MC; Rybkine T; Schramm EC; Java A; Atkinson JP; Aldigier JC; Bridoux F; Touchard G; Fremeaux-Bacchi V
J Am Soc Nephrol; 2016 Jun; 27(6):1665-77. PubMed ID: 26471127
[TBL] [Abstract][Full Text] [Related]
32. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
33. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
Hohenstein B; Amann K; Menne J
Internist (Berl); 2019 May; 60(5):458-467. PubMed ID: 30859280
[TBL] [Abstract][Full Text] [Related]
34. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
[TBL] [Abstract][Full Text] [Related]
35. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
36. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.
Figuères ML; Frémeaux-Bacchi V; Rabant M; Galmiche L; Marinozzi MC; Grünfeld JP; Noël LH; Servais A
Hum Pathol; 2014 Nov; 45(11):2326-33. PubMed ID: 25260719
[TBL] [Abstract][Full Text] [Related]
38. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).
Abrera-Abeleda MA; Nishimura C; Smith JL; Sethi S; McRae JL; Murphy BF; Silvestri G; Skerka C; Józsi M; Zipfel PF; Hageman GS; Smith RJ
J Med Genet; 2006 Jul; 43(7):582-9. PubMed ID: 16299065
[TBL] [Abstract][Full Text] [Related]
39. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
40. Dominant C3 glomerulopathy: new roles for an old actor in renal pathology.
Pirozzi N; Stoppacciaro A; Menè P
J Nephrol; 2018 Aug; 31(4):503-510. PubMed ID: 29151252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
